Overview of Addex Therapeutics’ Upcoming Annual General Meeting
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a pioneering biopharmaceutical firm focused on developing innovative allosteric modulators for neurological disorders, is gearing up for its Annual General Meeting (AGM) in 2025. The meeting is scheduled for June 24, 2025, and will be hosted at the Campus Biotech in Geneva, with doors opening at 10:30 am CEST.
Key Agenda Items for the AGM
The AGM is set to address several significant items:
- Approval of the Annual Report and Financial Statements for 2024
- Consultative vote on the Compensation Report for the previous year
- Discussion on the appropriation of results
- Discharge of Board members and Executive Management
- Re-elections within the Board, including the Chairman
- Approval of compensation packages for Board members and Executive Management
- Re-elections of members of the Compensation Committee
- Appointment of Auditors and Independent Voting Rights Representative
- Additional miscellaneous items
For detailed insights into the complete agenda, interested parties can visit the Annual General Meetings section of Addex's official website.
About Addex Therapeutics
Addex Therapeutics is a clinical-stage biopharmaceutical company at the forefront of developing new treatment options for neurological disorders. The company’s flagship drug candidate, dipraglurant, is an mGlu5 negative allosteric modulator (NAM) that is currently being evaluated for its potential in aiding recovery from brain injuries, including complications following strokes and traumatic injuries.
Their partners at Indivior have successfully completed essential studies for a GABAB PAM drug candidate aimed at treating substance use disorders. Furthermore, Addex is progressing with an independent GABAB PAM program specifically for chronic cough, showcasing its commitment to expanding therapeutic avenues.
In addition, the company has a 20% equity stake in Neurosterix LLC, which is advancing a range of allosteric modulator programs. These initiatives include M4 PAM for schizophrenia, mGlu7 NAM for mood disorders, and mGlu2 NAM for managing mild neurocognitive disorders. Notably, Addex’s shares are actively traded on both the SIX Swiss Exchange and the NASDAQ Capital Market under the symbol "ADXN".
Contact Information
For further inquiries, the following contacts are available:
Tim Dyer
Chief Executive Officer
Phone: +41 22 884 15 55
Email: PR@addextherapeutics.com
Mike Sinclair
Partner, Halsin Partners
Phone: +44 (0)7968 022075
Email: msinclair@halsin.com
Frequently Asked Questions
What is the date of the 2025 AGM for Addex Therapeutics?
The Annual General Meeting is scheduled for June 24, 2025.
Where will the AGM take place?
The AGM will be held at Campus Biotech in Geneva, Switzerland.
What key topics will be discussed at the AGM?
Key topics include approval of financial statements, election of Board members, and discussion of compensation for executives.
How is Addex Therapeutics innovating in drug development?
Addex is developing novel small molecule allosteric modulators targeting a range of neurological disorders.
How can I get in touch with Addex Therapeutics?
For inquiries, you can contact Tim Dyer or Mike Sinclair via email or phone as listed.
